ARUN SREEKUMAR to Mass Spectrometry
This is a "connection" page, showing publications ARUN SREEKUMAR has written about Mass Spectrometry.
Connection Strength
0.365
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.104
-
Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011 Dec 15; 71(24):7376-86.
Score: 0.087
-
Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer. 2019 03 15; 125(6):921-932.
Score: 0.036
-
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus. 2018 12; 4(6):907-915.
Score: 0.032
-
Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol. 2016 06; 195(6):1911-9.
Score: 0.029
-
EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget. 2015 Dec 15; 6(40):42651-60.
Score: 0.029
-
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.
Score: 0.025
-
The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology. 2012 Jun; 142(7):1483-92.e6.
Score: 0.022